WDR5-0103
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


WDR5-0103
Description :
WDR5-0103 (WD-Repeat Protein 5-0103) is a potent and selective WD repeat-containing protein 5 (WDR5) antagonist with a Kd of 450 nM. WDR5-0103 competitively binds to the peptide-binding pocket of WDR5, blocking the interaction between WDR5 and mixed-lineage leukemia (MLL) protein and inhibiting the methyltransferase activity of MLL. WDR5-0103 is mainly used in the research of cancer and neurodegenerative diseases[1][2][3].Product Name Alternative :
WD-Repeat Protein 5-0103UNSPSC :
12352005Hazard Statement :
H410Target :
WDR5Type :
Reference compoundRelated Pathways :
EpigeneticsApplications :
Cancer-programmed cell deathField of Research :
Cancer; Neurological DiseaseAssay Protocol :
https://www.medchemexpress.com/WDR5-0103.htmlPurity :
99.94Solubility :
DMSO : 50 mg/mL (ultrasonic)Smiles :
O=C(OC)C1=CC=C(N2CCN(C)CC2)C(NC(C3=CC=CC(OC)=C3)=O)=C1Molecular Formula :
C21H25N3O4Molecular Weight :
383.44Precautions :
H410References & Citations :
[1]Senisterra G, et al. Small-molecule inhibition of MLL activity by disruption of its interaction with WDR5. Biochem J. 2013 Jan 1;449 (1) :151-159.|[2]Wu CP, et al. The WD repeat-containing protein 5 (WDR5) antagonist WDR5-0103 restores the efficacy of cytotoxic drugs in multidrug-resistant cancer cells overexpressing ABCB1 or ABCG2. Biomed Pharmacother. 2022 Oct;154:113663. |[3]Cao Q, et al. Targeting histone K4 trimethylation for treatment of cognitive and synaptic deficits in mouse models of Alzheimer's disease. Sci Adv. 2020 Dec 9;6 (50) :eabc8096.Shipping Conditions :
Room TemperatureStorage Conditions :
-20°C, 3 years; 4°C, 2 years (Powder)Scientific Category :
Reference compound1Clinical Information :
No Development ReportedCAS Number :
[890190-22-4]

